CN103040839B - 药物组合物的用途及含有该用途的产品 - Google Patents
药物组合物的用途及含有该用途的产品 Download PDFInfo
- Publication number
- CN103040839B CN103040839B CN201310001299.8A CN201310001299A CN103040839B CN 103040839 B CN103040839 B CN 103040839B CN 201310001299 A CN201310001299 A CN 201310001299A CN 103040839 B CN103040839 B CN 103040839B
- Authority
- CN
- China
- Prior art keywords
- compound
- compositions
- free acid
- patient
- infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 104
- 239000003814 drug Substances 0.000 title claims abstract description 72
- 229940079593 drug Drugs 0.000 title abstract description 22
- 208000015181 infectious disease Diseases 0.000 claims abstract description 60
- 229940125904 compound 1 Drugs 0.000 claims description 118
- 229940125782 compound 2 Drugs 0.000 claims description 81
- 239000002253 acid Substances 0.000 claims description 56
- 230000000844 anti-bacterial effect Effects 0.000 claims description 42
- 230000002485 urinary effect Effects 0.000 claims description 34
- 108090000204 Dipeptidase 1 Proteins 0.000 claims description 32
- 102000006635 beta-lactamase Human genes 0.000 claims description 32
- 206010059866 Drug resistance Diseases 0.000 claims description 24
- 230000001154 acute effect Effects 0.000 claims description 22
- 230000001580 bacterial effect Effects 0.000 claims description 20
- 230000001684 chronic effect Effects 0.000 claims description 18
- 230000000694 effects Effects 0.000 description 34
- 238000002347 injection Methods 0.000 description 28
- 239000007924 injection Substances 0.000 description 28
- 238000011160 research Methods 0.000 description 23
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 21
- 238000012360 testing method Methods 0.000 description 21
- 238000002474 experimental method Methods 0.000 description 18
- 230000001225 therapeutic effect Effects 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 12
- 238000012216 screening Methods 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- 210000003462 vein Anatomy 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 230000003115 biocidal effect Effects 0.000 description 10
- 238000012258 culturing Methods 0.000 description 9
- 238000011125 single therapy Methods 0.000 description 9
- 206010060891 General symptom Diseases 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 208000019206 urinary tract infection Diseases 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 7
- 241000588747 Klebsiella pneumoniae Species 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 241000588697 Enterobacter cloacae Species 0.000 description 6
- 230000001186 cumulative effect Effects 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 230000035935 pregnancy Effects 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 206010037601 Pyelonephritis chronic Diseases 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 201000006368 chronic pyelonephritis Diseases 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 206010057190 Respiratory tract infections Diseases 0.000 description 4
- 241000191963 Staphylococcus epidermidis Species 0.000 description 4
- 230000000721 bacterilogical effect Effects 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 206010015037 epilepsy Diseases 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000027939 micturition Effects 0.000 description 4
- 230000003285 pharmacodynamic effect Effects 0.000 description 4
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 241000589291 Acinetobacter Species 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 208000015114 central nervous system disease Diseases 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 231100000027 toxicology Toxicity 0.000 description 3
- 229940124586 β-lactam antibiotics Drugs 0.000 description 3
- 241000588624 Acinetobacter calcoaceticus Species 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 238000012404 In vitro experiment Methods 0.000 description 2
- 201000008225 Klebsiella pneumonia Diseases 0.000 description 2
- 208000008930 Low Back Pain Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010035717 Pneumonia klebsiella Diseases 0.000 description 2
- 241000607762 Shigella flexneri Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 231100001252 long-term toxicity Toxicity 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 238000009527 percussion Methods 0.000 description 2
- 230000001374 post-anti-biotic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000588919 Citrobacter freundii Species 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000588770 Proteus mirabilis Species 0.000 description 1
- 241000588767 Proteus vulgaris Species 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 206010037597 Pyelonephritis acute Diseases 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 201000001555 acute pyelonephritis Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 239000003781 beta lactamase inhibitor Substances 0.000 description 1
- 229940126813 beta-lactamase inhibitor Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
- 230000001408 fungistatic effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000008353 injections by composition Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000000244 kidney pelvis Anatomy 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229940007042 proteus vulgaris Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 208000037922 refractory disease Diseases 0.000 description 1
- 230000036391 respiratory frequency Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
- 229940126085 β‑Lactamase Inhibitor Drugs 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310001299.8A CN103040839B (zh) | 2012-08-10 | 2013-01-04 | 药物组合物的用途及含有该用途的产品 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210284792.0 | 2012-08-10 | ||
CN201210284792 | 2012-08-10 | ||
CN201310001299.8A CN103040839B (zh) | 2012-08-10 | 2013-01-04 | 药物组合物的用途及含有该用途的产品 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103040839A CN103040839A (zh) | 2013-04-17 |
CN103040839B true CN103040839B (zh) | 2015-01-07 |
Family
ID=48053851
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310001299.8A Active CN103040839B (zh) | 2012-08-10 | 2013-01-04 | 药物组合物的用途及含有该用途的产品 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103040839B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1543958A (zh) * | 2003-11-25 | 2004-11-10 | 郭东宇 | 一种增强抗菌作用的药物组合物 |
CN1729987A (zh) * | 2005-08-19 | 2006-02-08 | 夏中宁 | 注射用头孢呋辛钠与舒巴坦钠组合物 |
CN1850047A (zh) * | 2006-06-01 | 2006-10-25 | 济南帅华医药科技有限公司 | 一种含β-内酰胺酶抑制剂和头孢菌素的缓释制剂及其应用 |
CN101648016A (zh) * | 2008-08-11 | 2010-02-17 | 广州威尔曼新药开发中心有限公司 | 稳定性高的药物组合物 |
-
2013
- 2013-01-04 CN CN201310001299.8A patent/CN103040839B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1543958A (zh) * | 2003-11-25 | 2004-11-10 | 郭东宇 | 一种增强抗菌作用的药物组合物 |
CN1729987A (zh) * | 2005-08-19 | 2006-02-08 | 夏中宁 | 注射用头孢呋辛钠与舒巴坦钠组合物 |
CN1850047A (zh) * | 2006-06-01 | 2006-10-25 | 济南帅华医药科技有限公司 | 一种含β-内酰胺酶抑制剂和头孢菌素的缓释制剂及其应用 |
CN101648016A (zh) * | 2008-08-11 | 2010-02-17 | 广州威尔曼新药开发中心有限公司 | 稳定性高的药物组合物 |
Also Published As
Publication number | Publication date |
---|---|
CN103040839A (zh) | 2013-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Warrell et al. | Treatment and prevention of malaria | |
Prescott Jr et al. | Continuous-infusion antipseudomonal Beta-lactam therapy in patients with cystic fibrosis | |
Bajjoka et al. | Risperidone-induced neuroleptic malignant syndrome | |
Perrone et al. | Lithium poisoning | |
KR101562608B1 (ko) | 호흡기 질환에 작용하는 복합 화학 약물, 그들의 제조 방법 및 용도 | |
CN103040839B (zh) | 药物组合物的用途及含有该用途的产品 | |
CN103040840B (zh) | 组合物的治疗应用及其产品 | |
CN103040838B (zh) | 一种药物组合物及其用途 | |
CN103933350B (zh) | 白及乙酸乙酯提取物的用途 | |
CN105617353A (zh) | 一种黏菌素口服给药组合物 | |
CN105663135A (zh) | 一种组合物及其产品和制药用途 | |
Thimann et al. | Benzonatate toxicity in a teenager resulting in coma, seizures, and severe metabolic acidosis | |
O'Callaghan et al. | Vincristine toxicity unrelated to dose. | |
CN103054874A (zh) | 组合物的用途及含有该用途的产品 | |
CN103054875A (zh) | 一种药物组合物及其产品和用途 | |
CN103142612B (zh) | 一种组合物的医药用途 | |
CN102988765B (zh) | 白及乙酸乙酯提取物的用途 | |
CN103142611B (zh) | 一种组合物产品在治疗细菌感染的制药应用 | |
CN103142613B (zh) | 一种药物组合物的用途 | |
CN103142614B (zh) | 一种组合物产品的制药应用 | |
CN110812357A (zh) | 比阿培南在制备防治牛肠道病毒感染药物中的应用 | |
CN101156841B (zh) | 一种联苯乙酸及其盐的抗肿瘤新用途 | |
CN109646435B (zh) | 厄他培南钠在制备防治牛传染性鼻气管炎药物中的应用 | |
CN105982909A (zh) | 阿奇霉素在治疗功能性肠蠕动乏力的药物中的应用 | |
CN103142610A (zh) | 一种组合物产品的制药应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170421 Address after: 518000 Shennan Road, Shenzhen, Guangdong, No. 6009, No. Patentee after: Mai Lifang Address before: No. 6007 Futian District Shennan Road Shenzhen city Guangdong province 518000 Patentee before: Ling Li |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200218 Address after: Futian District Shenzhen City, Guangdong province 518040 Shennan Road No. 6009 Che Kung Temple Green Plaza building 37 layer Patentee after: SHENZHEN SALUBRIS PHARMACEUTICALS Co.,Ltd. Address before: 518000 No. 6009 Shennan Avenue, Shenzhen, Guangdong, Futian District Patentee before: Mai Lifang |
|
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: Area A, 4th Floor, Digital Peninsula, No. 2, Hongliu Road, Fubao Community, Fubao Street, Futian District, Shenzhen, Guangdong, 518017 Patentee after: SHENZHEN SALUBRIS PHARMACEUTICALS Co.,Ltd. Address before: 518040 37th floor, chegongmiao Lvjing Plaza, 6009 Shennan Avenue, Futian District, Shenzhen City, Guangdong Province Patentee before: SHENZHEN SALUBRIS PHARMACEUTICALS Co.,Ltd. |